DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Long-Term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Eplerenone (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

To assess the long-term safety and toleration of eplerenone in the children aged 6 to 16 years with high blood pressure. The study will last at least 1 year and about 140 patients will participate.

Clinical Details

Official title: Peds II (Pediatric Eplerenone Development Study II)--An Open Label, Long-Term Study To Evaluate The Safety Of Eplerenone In The Treatment Of Hypertension In Children

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Safety of eplerenone in hypertensive children

Secondary outcome: Efficacy and pharmacokinetics of eplerenone in hypertensive children

Eligibility

Minimum age: 6 Years. Maximum age: 16 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Males and females aged 6 to 16 years

- The seated systolic blood pressure greater than or equal to the 95th percentile for

age, gender and height, measured on at least 3 separate occasions Exclusion Criteria:

- K/DOQI classification of stages of chronic kidney disease equal to 4 or 5

- Serum or whole blood potassium > 5. 5. mEq/L

Locations and Contacts

Pfizer Investigational Site, Chennai 600 031, India

Pfizer Investigational Site, Mumbai 400 012, India

Pfizer Investigational Site, New Delhi 110029, India

Pfizer Investigational Site, Moscow 119991, Russian Federation

Pfizer Investigational Site, Moscow 127412, Russian Federation

Pfizer Investigational Site, Moscow 117869, Russian Federation

Pfizer Investigational Site, Smolensk 214019, Russian Federation

Pfizer Investigational Site, St. Petersburg, Russian Federation

Pfizer Investigational Site, St. Petersburg 194100, Russian Federation

Pfizer Investigational Site, St. Petersburg 194291, Russian Federation

Pfizer Investigational Site, St. Petersburg 196191, Russian Federation

Pfizer Investigational Site, Hyderabad, Andhra Pradesh 500 033, India

Pfizer Investigational Site, Los Angeles, California 90048, United States

Pfizer Investigational Site, Park Ridge, Illinois 60068, United States

Pfizer Investigational Site, Bangalore, Karnataka 560034, India

Pfizer Investigational Site, Durham, North Carolina 27710, United States

Pfizer Investigational Site, Columbus, Ohio 43205, United States

Pfizer Investigational Site, Columbus, Ohio 43205-2696, United States

Pfizer Investigational Site, Chennai, Tamil Nadu 600 008, India

Pfizer Investigational Site, Houston, Texas 77030, United States

Pfizer Investigational Site, Katy, Texas 77094, United States

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: October 2004
Last updated: June 4, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017